Current Patterns and Best Practices for Prescribing Novel Heart Failure Medications in Children: A Science Advisory From the American Heart Association
Year: 2026
Type: article
Abstract: Robust evidence from randomized controlled trials of novel heart failure medications in adults has demonstrated improved quality of life, reduced hospitalizations, and decreased mortality, informing current treatment guidelines. In contrast, data supporting the clinical benefits of newer heart failure therapies in children remain limited. To assess contemporary prescribing practices and clinician perspectives, we surveyed pediatric heart failure physicians across the United States and Canada regarding the use of angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and iron replacement therapy in children. We also reviewed the existing pediatric literature and summarized reported side effects, dosing experience, and practical guidance for the use of these therapies in the absence of rigorous evidence.
Source: Circulation Heart Failure
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7236797351
